30 Days | P | 90 Days | P | |||
---|---|---|---|---|---|---|
Survivors, n = 35 | Non-survivors, n = 15 | Survivors, n = 33 | Non-survivors, n = 17 | |||
Demographics | ||||||
Male sex, n (%) | 24 (69) | 7 (47) | 0.12 | 18 (55) | 9 (53) | 0.54 |
Age, years, median (IQR) | 65 (56 to 71) | 75 (65 to 79) | 0.01 | 64 (54 to 71) | 72 (65 to 79) | 0.02 |
Weight, kg, median (IQR) | 74 (65 to 85) | 68 (64 to 80) | 0.42 | 72 (63 to 84) | 70 (64 to 81) | 0.86 |
Cardiac comorbidities, n (%) | 15 (43) | 9 (60) | 0.23 | 14 (42) | 10 (59) | 0.17 |
Clinical data and cardiac biomarkers | ||||||
Saps 3, median (IQR) | 70 (59 to 76) | 81 (70 to 88) | 0.03 | 68 (59 to 76) | 81 (70 to 88) | 0.01 |
ICU length of stay, days, median (IQR) | 115 (56 to 272) | 93 (23 to 142) | 0.13 | 168 (81 to 290) | 78 (23 to 143) | 0.02 |
Mechanical ventiltion, hours, median (IQR) | 70 (0 to 240) | 45 (9 to 135) | 0.77 | 154 (19 to 245) | 40 (2 to 118) | 0.17 |
Sequential organ failure assessment score | 10 (9 to 12) | 12 (9 to 14) | 0.62 | 10 (9 to 12) | 11 (9 to 14) | 0.61 |
PEEP, cmH2O | 14 (10 to 16) | 12 (10 to 15) | 0.73 | 12 (10 to 15) | 12 (10 to 15) | 0.91 |
Pmax, cmH2O | 28 (22 to 31) | 32 (26 to 34) | 0.18 | 28 (21 to 31) | 32 (26 to 34) | 0.21 |
Norepinephrine, ug/kg/min | 0.09 (0.05 to 0.14) | 0.11 (0.05 to 0.26) | 0.50 | 0.09 (0.06 to 0.16) | 0.08 (0.04 to 0.22) | 0.95 |
Dobutamine, ug/kg/min | 5.5 (3.1 to 8.2) | 5.4 (4.7 to 11.3) | 0.46 | 5.1 (3.1 to 8.8) | 5.6 (4.8 to 10.4) | 0.34 |
Fluids administered, ml/kg | 127 (100 to 154) | 89 (60 to 200) | 0.34 | 131 (100 to 154) | 90 (62 to 118) | 0.15 |
Fluid balance, ml/kg | 70 (33 to 95) | 21 to 151) | 0.99 | 71 (31 to 104) | 59 (23 to 132) | 0.96 |
Cardiac index, l/min/ m2 | 4.0 (3.3 to 5.0) | 5.0 (4.6 to 5.4) | 0.14 | 4.0 (3.2 to 5.1) | 4.9 (4.3 to 5.4) | 0.16 |
SVRI dyn × sec × cm−5/m2 | 1310 (1066 to 1582) | 800 (600 to 852) | 0.001 | 1,310 (1,062 to 1,585) | 801 (600 to 1045) | 0.002 |
NT-proBNP, ng/L | 4230 (1410 to 10400) | 7940 (2780 to 26400) | 0.15 | 4,070 (1,400 to 8,510) | 10,500 (2,860 to 30,700) | 0.03 |
High sensitivity troponin T, ng/L | 40 (24 to 119) | 121 (39 to 530) | 0.09 | 40 (26 to 236) | 115 (42 to 348) | 0.08 |
Echocardiography | ||||||
Global longitudinal peak strain, % | −17.2 (−20.0 to (−13.0)) | −15.0 (−19.7 to (−11.0)) | 0.34 | −17.4 (−20.5 to −13.6) | −14.7 (−19.0 to −10.6) | 0.11 |
Left ventricular ejection fraction, % | 50 (42 to 57) | 53 (37 to 59) | 0.99 | 50 (44 to 58) | 47 (36 to 56) | 0.47 |
E/é | 7.1 (5.9 to 11.0) | 7.7 (5.4 to 10.7) | 0.62 | 7.4 (6.0 to 11.7) | 7.4 (5.7 to 9.0) | 0.60 |
é, m/s | 0.11 (0.08 to 0.18) | 0.12 (0.83 to 0.16) | 0.99 | 0.11 (0.08 to 0.16) | 0.11 (0.08 to 0.16) | 0.95 |
E, m/s | 0.97 (0.79 to 1.07) | 0.95 (0.61 to 1.07) | 0.53 | 0.98 (0.79 to 1.08) | 0.95 (0.60 to 1.11) | 0.46 |
A, m/s | 0.73 (0.57 to 0.92) | 0.99 (0.845 to 1.20) | 0.31 | 0.73 (0.59 to 0.89) | 0.81 (0.47 to 1.48) | 0.34 |
E/A | 1.2 (1.0 to 1.7) | 1.0 (0.8 to 1.2) | 0.10 | 1.2 (1.0 to 1.7) | 1.1 (0.9 to 1.2) | 0.60 |
DT, ms | 157 (140 to 197) | 171 (105 to 200) | 0.97 | 156 (140 to 199) | 172 (126 to 204) | 0.93 |